COVID-19 and isolation: Risks and implications in the scenario of new variants

Imagem de Miniatura
Arquivos
art_DIAS_COVID19_and_isolation_Risks_and_implications_in_the_2022.PDF (446.21 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER BRAZIL
Autores
DIAS, Viviane Maria de Carvalho Hessel
OLIVEIRA, Alexandre Ferreira
FERREIRA, Carlos Eduardo dos Santos
DOMINGUES, Carlos Eduardo Ferreira
FORTALEZA, Carlos Magno Castelo Branco
VIDAL, Claudia Fernanda de Lacerda
CARRILHO, Claudia Maria Dantas de Maio
PINHEIRO, Debora Otero Britto Passos
ASSIS, Denise Brandao de
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.26, n.5, article ID 102703, 11p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
With the emergence of new variants of SARS-CoV-2, questions about transmissibility, vac-cine efficacy, and impact on mortality are important to support decision-making in public health measures. Modifications related to transmissibility combined with the fact that much of the population has already been partially exposed to infection and/or vaccination, have stimulated recommendations to reduce the isolation period for COVID-19. However, these new guidelines have raised questions about their effectiveness in reducing contami-nation and minimizing impact in work environments. Therefore, a collaborative task force was developed to review the subject in a non-systematic manner, answering questions about SARS-CoV-2 variants, COVID-19 vaccines, isolation/quarantine periods, testing to end the isolation period, and the use of masks as mitigation procedures. Overall, COVID-19 vaccines are effective in preventing severe illness and death but are less effective in pre-venting infection in the case of the Omicron variant. Any strategy that is adopted to reduce the isolation period should take into consideration the epidemiological situation of the geo-graphical region, individual clinical characteristics, and mask for source control. The use of tests for isolation withdrawal should be evaluated with caution, due to results depending on various conditions and may not be reliable.(c) 2022 Sociedade Brasileira de Infectologia.
Palavras-chave
COVID-19, Isolation period, Masks, SARS-CoV-2 variants, Vaccines, SARS-CoV-2 testing
URI
https://observatorio.fm.usp.br/handle/OPI/50546
Referências
  1. Alexandersen S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19883-7
  2. Altarawneh HN, 2022, NEW ENGL J MED, V387, P21, DOI 10.1056/NEJMoa2203965
  3. Andrejko KL, 2022, CLIN INFECT DIS, V75, pE276, DOI 10.1093/cid/ciab1040
  4. Araf Y, 2022, J MED VIROL, V94, P1825, DOI 10.1002/jmv.27588
  5. Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1056/NEJMoa2001316, 10.1001/jama.2020.2565]
  6. Bentley E., 2021, SARS COV 2 OMICRON B, DOI 10.1101/2021.12.26.474085
  7. Bond KA, 2022, LANCET REG HEALTH-W, V25, DOI 10.1016/j.lanwpc.2022.100486
  8. Brasil, 2022, MIN SAUD GUIA VIG EP
  9. Brasil. Agencia nacional de vigilancia santaria (ANVISA), 2022, OR PREV VIG EP INF S
  10. Brasil Ministerio do Trabalho e Previdencia, 2022, PORT INT MTP MS 14 2
  11. Carneiro M, 2022, INFECT CONT HOSP EP, V43, P550, DOI 10.1017/ice.2021.41
  12. CDC, 2021, SCI BRIEF COVID 19 V
  13. CDC, 2022, TYP MASKS RESP
  14. Cele S, 2022, NATURE, V602, P654, DOI 10.1038/s41586-021-04387-1
  15. Centers for Disease Control USA (CDC), 2021, POT RAP INCR OM VAR
  16. Centers for Disease Control USA (CDC), 2022, CDC UPD SHORT REC IS
  17. Centers for Disease Control USA (CDC), 2022, END IS PREC PEOPL CO
  18. Centers for Disease Control USA (CDC), 2022, YOUR GUID MASKS
  19. Centrer for diseases control CDC E, 2022, STAY DAT YOUR COVID
  20. Costa SF, 2022, AM J INFECT CONTROL, V50, P707, DOI 10.1016/j.ajic.2021.12.004
  21. Deng ZP, 2022, INDOOR AIR, V32, DOI 10.1111/ina.12935
  22. Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916
  23. Enrique B, 2020, INT ARCH PUBLIC HEAL, V4, P3
  24. Ferreira CE, 2021, INT J INFECT DIS, V103, P260, DOI 10.1016/j.ijid.2020.11.173
  25. Fiocruz, BRAS CEL AN VAC COVI
  26. Fiocruz, 2021, AV DIG CAMP VAC COVI
  27. Fiolet T, 2022, CLIN MICROBIOL INFEC, V28, P202, DOI 10.1016/j.cmi.2021.10.005
  28. Fletcher JJ, 2022, INFECT CONT HOSP EP, V43, P490, DOI 10.1017/ice.2021.167
  29. Furukawa Nathan W, 2020, Emerg Infect Dis, V26, DOI 10.3201/eid2607.201595
  30. Gans JS, 2022, JAMA-J AM MED ASSOC, V327, P485, DOI 10.1001/jama.2021.24355
  31. Garcia-Beltran WF, 2022, CELL, V185, P457, DOI [10.1016/j.cell.2021.12.033, 10.1101/2021.12.14.21267755]
  32. Goga A., 2021, MEDRXIV, DOI [10.1101/2021.12.21.21268171, DOI 10.1101/2021.12.21.21268171]
  33. Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
  34. Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8
  35. Haller S., 2021, MEDRXIV
  36. Haque A, 2022, J AUTOIMMUN, V127, DOI 10.1016/j.jaut.2021.102792
  37. Hay JA., 2022, MEDRXIV, DOI [10.1101/2022.01.13.22269257, DOI 10.1101/2022.01.13.22269257, DOI 10.1101/2022.01.13.22269257V1]
  38. Hessel Dias VMC, 2020, J INFECT CONTROL, V9, P90
  39. Hessel Dias VMH, 2020, J INFECT CONTROL, V9, P56
  40. Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
  41. Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715
  42. Jegerlehner S, 2021, INT J INFECT DIS, V109, P118, DOI 10.1016/j.ijid.2021.07.010
  43. Klompas M, 2021, JAMA-J AM MED ASSOC, V326, P2018, DOI 10.1001/jama.2021.19063
  44. Krause PR, 2021, LANCET, V398, P1377, DOI 10.1016/S0140-6736(21)02046-8
  45. Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
  46. Leung NHL, 2021, NAT REV MICROBIOL, V19, P528, DOI 10.1038/s41579-021-00535-6
  47. Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
  48. Liu Y, 2022, ANTIMICROB RESIST IN, V11, DOI 10.1186/s13756-021-01039-x
  49. Maslo C, 2022, JAMA-J AM MED ASSOC, V327, P583, DOI 10.1001/jama.2021.24868
  50. Modes Matthew E, 2022, MMWR Morb Mortal Wkly Rep, V71, P217, DOI 10.15585/mmwr.mm7106e2
  51. National Institute of Infectious Diseases Disease Control and Prevention Center National Center for Global Health and Medicine J, ACT EP INV SARS COV, P1
  52. Perera RAPM, 2020, EMERG INFECT DIS, V26, P2701, DOI 10.3201/eid2611.203219
  53. Piapan L, 2020, J HOSP INFECT, V106, P626, DOI 10.1016/j.jhin.2020.08.012
  54. Prevention EC for D, 2020, EUR CENT DIS PREV, P1
  55. Pulliam JRC, 2022, SCIENCE, V376, P596, DOI 10.1126/science.abn4947
  56. Ranzani O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2015
  57. Rhee C., 2020, CLIN INFECT DIS, V72, P1467, DOI [10.1093/cid/ciaa1249, DOI 10.1093/CID/CIAA1249]
  58. Riediker M, 2022, SWISS MED WKLY, V152, DOI [10.4414/smw.2022.w30133, 10.4414/SMW.2022.w30133]
  59. Rodrigues CMC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01526
  60. Rossler A, 2022, NEW ENGL J MED, V386, P698, DOI 10.1056/NEJMc2119236
  61. Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
  62. Shapiro J., 2021, MEDRXIV, DOI [10.1101/2021.05.20.21257461v2%0A, DOI 10.1101/2021.05.20.21257461V2%0A]
  63. Sigal A, 2022, NAT REV IMMUNOL, V22, P69, DOI 10.1038/s41577-022-00678-4
  64. Sims MD, 2021, CLIN INFECT DIS, V73, pS154, DOI 10.1093/cid/ciaa1684
  65. Tom MR, 2020, CLIN INFECT DIS, V71, P2252, DOI 10.1093/cid/ciaa619
  66. Tseng HF, 2022, NAT MED, V28, P1063, DOI 10.1038/s41591-022-01753-y
  67. van Kampen JJA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20568-4
  68. Van Kerkhove MD, 2021, NAT MED, V27, P2070, DOI 10.1038/s41591-021-01616-y
  69. Venugopal U, 2021, INT J INFECT DIS, V102, P63, DOI 10.1016/j.ijid.2020.10.036
  70. Wagner J, 2021, J OCCUP ENVIRON HYG, V18, P495, DOI 10.1080/15459624.2021.1963445
  71. who, WHO TRACK SARS COV 2
  72. Wilder-Smith A, 2022, LANCET INFECT DIS, V22, P152, DOI 10.1016/S1473-3099(21)00690-3
  73. Wolfel R, 2020, NATURE, V588, pE35, DOI 10.1038/s41586-020-2984-3
  74. World Health Organization, 2020, COMMUNICATION
  75. World Health Organization, WHO COR COVID 19 DAS
  76. World Health Organization, 2021, COR DIS COVID 19 OUT
  77. Yang W, 2021, MEDRXIV

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/IOT
Artigos e Materiais de Revistas Científicas - LIM/41
Artigos e Materiais de Revistas Científicas - LIM/49
Carregar mais